C09988776 / invoice 10000

Species:CANINE
Breed:Poodle - Toy
Age (years):9
Diagnosis or signs:acth stim test
Consult notes

Animal clinical history (3 most recent)

2026-03-05T00:00:00Z 10:20 AM
Reason: Admit for ACTH stim test History: Trilostane 20mg/ml 0.6ml given this morning @ 6am (also gets 0.6mls in the pm) All OK - perhaps slightly less urination. Plan: Aim to pick her up by 11.45 am please. ACTH stim testProtocol - ideally fasted dog (If on trilostane - Perform the test 4-6 hours after administration of trilostane)1. Collect blood - plain tube, t=02. Inject 0.2ml synacthen IV RF @ 10.35am 3. Collect blood in plain tube (red top) at EXACTLY 1 hr after step 2, label t=1To run cortisol test;Need serumAssessment - Interpretation;* diagnosising cushings - resting cortsiol, t=0 should be normal or high (2-6ug/dl = 55-165nmol/L), t=1 should be much higher (18-22ug/dl - equivocal; > 22ug/dl = >607nmol/L => failure to suppress  * if assessing effectivness of treatment => want resting and post acth stim cortisol to be <75nmol charges reflect inclusion of rt consult fee For Monitoring: Key pearls to put into practice:Trilostane therapy that starts with 0.5 to 1 mg/kg PO every 12 hours and gradually increases in dose is recommended for treatment of pituitary-dependent hyperadrenocorticism in dogs to minimize signs of hypoadrenocorticism.Periodic (ie, every 4-6 weeks) ACTH stimulation testing is recommended to monitor trilostane therapy. cpACTH >7 micrograms/dL, particularly when noted concurrently with unresolved clinical signs, indicates a dose increase is warranted. Dose escalation is common, possibly due in part to adrenal hyperplasia during therapy.Pet owners should be informed that cpACTH =27 micrograms/dL at the time of diagnosis indicates the trilostane dose will likely need to be gradually increased to achieve disease control. As basal (ie, pre-ACTH) cortisol had no predictive value in this study, basal cortisol measurement may be eliminated as a cost-savings measure, especially in patients without signs of hypoadrenocorticism.Most studies have evaluated dosage and efficacy of commercially available trilostane. Greater variability should be expected from compounded trilostane.    Vital Signs    

Previous claim history (19)

DateClaim #Diagnosis
2026-01-19C09799276HYPERADRENOCORTICISM ("CUSHING'S")
2026-01-16C09766539HYPERADRENOCORTICISM ("CUSHING'S")
2023-12-22C6714201SCOOTING
2023-11-30C6593907GASTROINTESTINAL PROBLEMS
2023-11-24C6754146PRESCRIPTION DIETS
2023-11-13C6519903DIARROHEA
2023-11-13C6533115GASTROINTESTINAL PROBLEMS
2023-11-03C6488928DIARROHEA
2023-10-27C6754146FLEA/TICK/WORM CONTROL
2023-07-15C6111140VACCINATIONS OR HEALTH CHECKS
2023-07-15C6111140ALTERNATIVE THERAPIES
2023-05-06C5865004DIARRHOEA - PRESUMED SELF-LIMITING
2023-02-10C5584098DENTAL (TOOTH) DISORDER
2022-11-04C5333488PATELLA LUXATION
2022-07-02C4887192VACCINE REACTION
2022-07-01C4887183Grooming
2022-07-01C4887183VACCINATIONS OR HEALTH CHECKS
2022-07-01C4887183FLEA/TICK/WORM CONTROL
2022-04-14C4663461GASTROINTESTINAL PROBLEMS

Line items(lines with upstream diagnosis are skipped by the model)

LinetstarcAmountDateUpstream diagnosis
10000tstarc_hospitalisation125.012026-03-05
20000tstarc_diagnostic_test_-_acth_stimulation_test311.202026-03-05
30000tstarc_consultation-revisit110.002026-03-05
40000tstarc_synacthen150.292026-03-05

UPM+

  • DG02293HYPERADRENOCORTICISM ("CUSHING'S")DSTP_hyperadrenocorticism_(cushing's_disease)

Variant (sleepy_king)

HYPERADRENOCORTICISM ("CUSHING's")
DSTP_hyperadrenocorticism_(cushing's_disease)
Conf: 0.990
Threshold: 0.18
Above:
Correct?